What South Korea’s pricing reforms mean for global pricing, access, and launch decisions
South Korea is implementing its most significant drug pricing overhaul in over a decade, with direct implications for how pharmaceutical manufacturers plan pricing, access, and launch sequencing across global markets.
The reforms expand dual pricing, tighten generic price controls, and introduce new incentives tied to innovation and supply stability, shifting how value is distributed across therapy areas.
To clarify what is changing and why it matters, Trinity analyzed South Korea’s current pricing and reimbursement system alongside the 2025–2026 reform package and its downstream commercial impact.
This advisory brief answers:
- How the Health Insurance Review and Assessment Service (HIRA) and the National Health Insurance Service (NHIS) will apply the new rules across assessment, price setting, and negotiation.
- How expanded dual pricing, deeper generic price cuts, and updated post-management timelines alter pricing dynamics for new drugs, off‑patent brands, biosimilars, and niche products.
- How these reforms may influence South Korea’s role as a reference market and affect global pricing corridors, launch sequencing, and portfolio decisions.
Complete the form below to access the advisory brief.
By clicking "I agree" above, you are agreeing that Trinity will use and protect your personal data in accordance with our Privacy Policy. You can opt out of future marketing communications at any time by clicking the unsubscribe link at the bottom of any marketing email you receive from Trinity.